A PYMNTS Company

US: Mylan passes final approval for Meda purchase

By  |  July 28, 2016

Mylan NV has received FTC approval for its $7.2 billion purchase of Swedish rival Meda, under the condition that Mylan divests rights to two generic drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The FTC said the deal could threaten the market for carisoprodol tablets, which treat muscle spasms and stiffness. Per FTC orders, Mylan will relinquish its U.S. marketing rights for the drug, allowing the drug’s maker Indicus Pharma to “compete independently in the U.S. market.”

    FTC approval was the final regulatory step needed to complete the Medadeal, following approval by the European Commission a week ago with the requirement of several  asset sales in various European countries.

    Full Content: Marketwatch

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.